Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5718 in coronary artery disease
2017-001582-25Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronary arteriosclerosis comparing AZD5718 with Placebo (2 arms). Primary endpoint: Inhibition of urinary leukotriene E4. Started Aug 2017; status: completed.
02
Drugs
atuliflapon
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2017-001582-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001582-25.